A Review of the Pathophysiology and Novel Treatments for Erectile Dysfunction by Lasker, George F. et al.
Hindawi Publishing Corporation
Advances in Pharmacological Sciences
Volume 2010, Article ID 730861, 10 pages
doi:10.1155/2010/730861
Review Article
AReview of the Pathophysiology and Novel Treatmentsfor
ErectileDysfunction
George F. Lasker,Jason H.Maley, andPhilip J. Kadowitz
Department of Pharmacology, Tulane University School of Medicine, 1430 Tulane Avenue, SL83, New Orleans, LA 70112-2699, USA
Correspondence should be addressed to Philip J. Kadowitz, pkadowi@tulane.edu
Received 27 April 2010; Accepted 3 June 2010
Academic Editor: Christoph H. Gleiter
Copyright © 2010 George F. Lasker et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Erectile dysfunction (ED) aﬀects up to 50% of men between the ages of 40 and 70. Treatment with PDE-5 inhibitors is eﬀective in
the majority of men with ED. However, PDE-5 inhibitors are not eﬀective when levels of nitric oxide (NO), the principle mediator
of erection, are low. The pharmacologic actions of three new potential treatments for ED are discussed in this paper: (1) sGC
stimulators/activators, (2) Rho-kinase inhibitors, and (3) sodium nitrite.
1.Introduction
The process of achieving penile erection involves the integra-
tion of psychological, neurological, and vascular processes,
which combine to initiate a physiologic response within
the penile vasculature. Endothelial mediated dilation of
arteriolar smooth muscle results in increased blood ﬂow into
the sinusoids of the corpora cavernosum and subsequent
ﬁlling while simultaneously relaxing to increase compliance.
This ﬁlling obstructs venous outﬂow from the penis by
compression of the veins against the tunica albuginea,
resulting in penile erection.
Erectile dysfunction is deﬁned as a diﬃculty in initiating
or maintaining penile erection adequate for sexual relations.
One of the largest current studies of ED, the Massachusetts
Male Aging Study, found that ED may be present in up to
half of the male population between 40 and 70 years old
[1]. This condition has been estimated to aﬀect 150 million
individuals worldwide [2] and data from the ENIGMA
study in 2004 suggested that the condition is prevalent in
approximately17% of allEuropeanmen [3].EDmaypresent
with comorbidities of hypertension, diabetes mellitus, obe-
sity, and atherosclerosis [4–6]. Alcoholism, illicit drug use,
and pharmacologic agents such as β-blockers, diuretics, and
antidepressants have also been suggested to play a role in the
etiology of ED [7, 8].
2. Characterization of ED
Erectiledysfunctioncanbeclassiﬁedasdeveloping frompsy-
chological, neurological, hormonal, and vascular patholo-
gies, or combinations of these factors [8].
2.1. Psychological. Psychological factors such as stress,
depression, schizophrenia, and a lack of sexual arousability
lead to diﬃculty in achieving an erection. ED may be caused
by diseases that interfere with libido, and therefore the
brain’s perception of arousal, such as Alzheimer’s, stroke,
Parkinson’s, or brain trauma. Injury to the spinal cord may
interrupt neural pathways to the sacral region, preventing or
inhibiting the process of achieving an erection [9].
2.2. Hormonal. Hormones such as adrenocorticotropic hor-
mone, oxytocin, prolactin, and androgens, especially testos-
terone, have been implicated in the modulation of erectile
function [8]. Hypogonadism plays a signiﬁcant role in
erectile dysfunction as it is believed that a threshold level of
testosteroneisnecessaryforerectiontooccur,andasmenage
there is a natural decrease in testosterone production further
contributing to ED [10].
2.3. Vascular. Peripheral arterial disease and endothelial dys-
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disease,andhypertensionalsocontributetothedevelopment
of ED [11]. It has also been hypothesized that ED is an early
harbinger of cardiovascular disease [12]. Along with these
causes, failure to occlude venous outﬂow from the sinusoids
of the corpora can be a contributing factor for ED. This may
develop from degeneration of the tunica albuginea, loss of
myogenic venous responses, trauma, or endothelial/smooth
muscle dysfunction in the corpora [13].
2.4. Nitric Oxide and ED. NO is thought to be the main
vasoactive neurotransmitter involved in the erectile response
andisreleasedfromnonadrenergic,noncholinergic(NANC)
neurons as well as from the endothelium [8, 14, 15]. An erec-
tion is dependent primarily upon a neurovascular, NANC
mechanism peripherally, and on the central nervous system
[8, 14]. Nitric oxide synthase is the enzyme responsible
for the conversion of L-arginine to NO and L-citrulline.
NOS has been identiﬁed within neuronal tissue (nNOS),
endothelium (eNOS), and epithelial tissue within pelvic
and urogenital structures of males [16, 17]. In addition
to NO released from NANC nerves, shear forces also
stimulate NO production by eNOS in the endothelium.
NO diﬀuses across smooth muscle cell membrane and
activates soluble guanylate cyclase (sGC), which in turn
catalyzes production of cGMP from intracellular GTP. A
cGMP-dependent protein kinase is activated, membrane
hyperpolarization occurs through potassium channels in the
smooth muscle cell membrane and there is an increase in
uptake of Ca2+ into stores (endoplasmic reticulum). This
hyperpolarization leads to blockade of membrane Ca2+
channels, decreasing calcium inﬂux and causing smooth
muscle cell relaxation. This relaxation produces dilation
of arteries/arterioles resulting in increased blood ﬂow into
corporal sinuses in both systolic and diastolic phases. The
cavernosal sinuses expand while trapping arterial inﬂow.
Compression of the subtunical venous plexuses between the
tunicaalbugineaandtheperipheralsinusoidsreducesvenous
outﬂow from the penis. Additionally, the tunica stretches
to capacity and further occludes emissary veins between
the inner circular and longitudinal layers further decreasing
venous outﬂow. The partial pressure of oxygen increases
from 35mm Hg to 90mmHg and the intracavernosal
pressure reaches approximately 100mm Hg which raises
the penis from a ﬂaccid nonerectile state to a fully erect
state (full-erection phase) [18]. Additional pressure increase
results from contraction of the ischiocavernosus muscles
(rigid erection phase) [19]. When the smooth muscle is
then contracted, arterial inﬂow is reduced to a minimum
and the penis assumes a ﬂaccid state. A cGMP-speciﬁc
phosphodiesterase (type 5) breaks down the cGMP to GTP
and terminates membrane hyperpolarization, attenuating
the relaxation of vascular smooth muscle cells.
NO is intimately involved in many of the known
etiologies and comorbidities of ED. Endothelial dysfunction
is caused by a decrease in formation or increase in oxidation
of NO. Due to this dysfunction, the penis is not perfused
suﬃciently to ﬁll the cavernosal sinusoids and cause an
erection. This lack of endothelial dependent vasodilation
links ED with diabetes, CVD, and hypertension- empha-
sizing the vital role that loss of endothelial/NO-dependent
vasodilation plays in ED [11]. Reactive oxygen species (ROS)
have also been implicated in type 1 diabetic ED and studies
demonstrating that blockade of ROS prevent impairment
of NO-mediated vasodilation [20]. Another major process
linking NO and ED is impairment of NANC nerves or
nNOS mediated NO release. Studies have found that type
1 diabetic animals have dysfunctional relaxation of the
corpora cavernosa in response to electrical stimulation,
which indicates a NANC nerve impairment [11]. Type 2
diabetic animal models have also been found to be deﬁcient
in penile nNOS [21].
3. CurrentTherapies
The current standard of care for ED consists of lifestyle
changes such as management of diet, diabetes, hypertension,
and weight loss, along with pharmacotherapies. The current
gold standard treatment is the use of phosphodiesterase
5 inhibitors such as sildenaﬁl citrate. As previously men-
tioned, phosphodiesterase 5 (PDE-5) is responsible for the
breakdown of cGMP within the corpora cavernosa and the
initiation of detumescence. PDE-5 inhibitors prevent this
breakdown of cGMP and subsequently promote the erectile
response. An individual receiving treatment for ED must be
psychologically sexually stimulated to induce a NO releasing
response from NANC nerve terminals initiating the sGC
cascade, resulting in an increase in cGMP levels. The action
of these drugs are based upon intact NO releasing neural
ﬁbers(nNOS)andcorporalendothelium(eNOS).Therefore,
these drugs are not eﬀective in vascular diseases where
endothelial dysfunction is signiﬁcant and NO bioavailability
may be impaired [7]. Sildenaﬁl citrate was the ﬁrst oral
type 5 phosphodiesterase inhibitor available for treatment
of ED, and has been joined on the market more recently
by vardenaﬁl and tadalaﬁl. Sildenaﬁl is 40% bioavailable
after oral administration and is contraindicated in patients
taking nitrates for angina pectoris due to the potential for a
severe drop in blood pressure [22, 23]. Flushing, headache,
and visual disturbances (PDE-6 inhibition) have also been
reported as side eﬀects with use of sildenaﬁl citrate [7].
Vardenaﬁl and tadalaﬁl are newer in the market than
sildenaﬁl, and oﬀer alternatives due to slight diﬀerences
in their ring structures. Vardenaﬁl, with a bioavailability
of 15% after oral administration, may beneﬁt from these
structural changes through stronger binding interaction to
the PDE-5 catalytic site. Tadalaﬁl, however, diﬀers in that
the piperazine ring on vardenaﬁl and sildenaﬁl is completely
replaced with a hydantoin ring. Crossover trials have shown
that men with ED prefer tadalaﬁl to sildenaﬁl by up to a
9:1margin[24]. This preference is increased in men with
diabetes or hypertension, and is not signiﬁcantly related to
whether they had previously taken sildenaﬁl [24]. Tadalaﬁl
has an increased half life, 17.5 hours, over sildenaﬁl and
vardenaﬁl, 4-5 hours, allowing patients a longer window of
time for sexual activity after taking the medication [25].
Because of this signiﬁcantly prolonged half-life of tadalaﬁl,Advances in Pharmacological Sciences 3
a daily dosage may be taken so that one is always prepared
for sexual activity.
4. RelatedDisease States
Despite the successful use of PDE-5 inhibitors, there is still a
signiﬁcant population of patients that remain refractory to
this therapy. ED in individuals with chronic disease states
such as diabetes mellitus (DM) and cardiovascular disease
(CVD) often remains refractory because of the reliance
of these drugs on functional NO release. Therefore, the
examination of these disease states may provide useful
insight into the etiologies of ED.
4.1.Diabetes. TheMassachusettsMaleAgingStudy(MMAS)
found that diabetic men are 3 times more likely to develop
ED compared to their nondiabetic counterpart [1]. In
diabetic men, peripheral vasculopathy and neuropathy are
intimately involved in the development of ED. Chronic
hyperglycemia may lead to micro- and macrovasculopa-
thy, including endothelial dysfunction. Autonomic and
peripheral neuropathies also develop commonly in these
individuals with poor glycemic control. The risk factors
for diabetic ED include glycemic control, advanced age,
duration of diabetes, and diabetic complications such as
retinopathy. Hyperlipidemia, hypertension, and obesity are
also all independent risk factors for diabetic men [26].
4.2. Cardiovascular Disease. Cardiovascular diseases and
erectile dysfunction are closely related because both disease
states involve impaired vascular endothelial function and
decrease bioavailability of NO. Therefore, a high copreva-
lence between ED and CVD exists. Risk factors such as
hypertension, hypercholesterolemia, smoking, and diabetes
mellitus are also common between the two disease states
[11]. It is logical that microvascular disease associated with
ED should precede macrovasculopathies and studies have
found that ED is signiﬁcantly associated with CVD as
well as CVD mortality [27, 28]. However, ED does not
improve prediction of CVD beyond the traditional risk
factorsincludedintheFraminghamriskscore[27].Standard
therapy of PDE-5 inhibitors is strongly contraindicated in
patients who are taking nitrates, as this may lead to severe
hypotension and even death, thus further excluding these
patients from current therapies [29]. In men with hyper-
tension, arterial stenosis, rather than high-blood pressure, is
associatedwiththedevelopmentofED[8].Ithasbeenshown
in spontaneously hypertensive rats that vascular relaxation,
dependent on cavernosal endothelium and nitric oxide
donors, is inhibited before systemic vascular changes occur.
This suggests that changes to the endothelium associated
with ED may precede systemic endothelial dysfunction in
hypertensive patients. Oxidative damage from superoxide
anion may also be important in the association between
ED and hypertension [11]. In human subjects, hypertension
has been correlated with a decrease in endothelial mediated
smooth muscle relaxation and it has been proposed that
NO may be unable to overcome the sympathetic neural
activity and other procontractile mediators that are involved
in establishing/maintaining the penis in a ﬂaccid state
(e.g.,ET-1,neuropeptideY,prostanoids,norepinephrineand
angiotensin II, etc.) [30]. In vivo studies in rodents to model
ischemia/hypertension have been performed using an iliac
artery ligation to reduce perfusion [31]. This procedure
results in a decrease in both the myelinated and nonmyeli-
nated ﬁber diameter of nerves innervating the penis, cor-
poral smooth muscle depletion of myoﬁlaments and fewer
endothelial cells surrounding the vasculature [31]. Because
endothelial dysfunction has been associated with a variety
of detrimental vascular diseases such as atherosclerosis,
hypertension, and hypercholesterolemia, it was determined
at the Second Princeton Consensus Conference (2006) that
ED is a telltale warning sign of silent vascular disease and
that a man with ED without cardiac symptoms should be
considered as an “at risk” cardiovascular patient until proven
otherwise [12].
4.3. Drug-Induced ED. It has been reported that the side
eﬀects of certain pharmacological agents may play a role
in up to 25% of newly presenting ED cases [32]. Antihy-
pertensive drugs can produce ED as a side eﬀect. Thiazide
diuretics have been reported to produce more ED than
other antihypertensive agents [33]. A clear mechanism has
not yet been elucidated, though it has been suggested
that diuretics interfere with smooth muscle relaxation [33].
Calcium channel antagonists and ACE inhibitors have
fewer detrimental eﬀects on sexual function than diuretics,
centrally acting-agents and beta-blocking therapies [34].
The aldosterone antagonist, spironolactone, is commonly
prescribedforheartfailureandcanbeusedforhypertension.
It can lead to ED by what is thought to be an antiandrogenic
mechanism where hydrotestosterone is completely inhibited
from binding androgenic receptors due to the structural
similarity of spironolactone to androgens [35]. Atenolol
and propranolol are two β-blocking agents that have been
associated with ED due to their antiadrenergic eﬀects as well
as mild psychological depression resulting in reduced libido
[36]. Centrally acting antihypertensives such as clonidine
can act to inhibit erectile function by depressing adrenergic
output. Methyldopa has a similar side eﬀect proﬁle in
respect to ED with greater prevalence when compared to
clonidine [37–40]. Many antidepressant pharmacotherapies
report ED as a common side eﬀect [8]. Increased prolactin
levelsassociatedwiththeuseoftheH2-antagonistcimetidine
and the phenothiazine antipsychotics, chlorpromazine and
thioridazine, have also been associated with ED [41–43].
4.4. Priapism. Priapism is deﬁned as an erection that lasts
more than 4 hours beyond sexual stimulation or that is not
relatedtosexualstimulation[44].Theprolongeddurationof
erection associated with ischemic and intermittent priapism
can result in destruction of sinusoidal endothelium and
necrosis of cavernosal smooth muscle cells [45]. Priapism
is prevalent in patients with sickle cell disease (SCD). In
SCD, free hemoglobin is reported to act as a scavenging
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Figure 1: Pathway for the control of penile erection and detumescence. Stimulation of erection originates in the higher centers of the
brain that result in upregulation of NANC and cholinergic activity and withdrawal of sympathetic activity in the nerves innervating the
corpora cavernosa and small arteries of the penis. This increase in NANC and cholinergic activity results in upregulated NO release from
the endothelium and NANC nerve terminals. The NO diﬀuses into the smooth muscle of the corpora cavernosa and small arteries/arterioles
of the penis and binds to the reduced heme iron of soluble guanylate cyclase, activating the enzyme and increasing the formation of cGMP
from GTP. cGMP-dependent protein kinase activity opens potassium channels in smooth muscle cells and increases the uptake of calcium
into stores. This leads to a decrease in intracellular calcium concentration and smooth muscle cell relaxation. This increases blood ﬂow
into the corporal sinuses and the cavernosal sinuses expand trapping blood in the corpora producing a penile erection. Detumescence is
initiated by release of vasoconstrictors from sympathetic terminals and endothelium. A cGMP speciﬁc phosphodiesterase (type 5) breaks
down the cGMP to GTP and terminates the actions of cGMP. Three new pharmacologic targets for the treatment of erectile dysfunction
(sGC stimulators/activators, Rho-kinase inhibitors and sodium nitrite) have been identiﬁed and may be eﬀective in patients refractory to
phosphodiesterase 5 inhibitor treatment. Recent experiments have shown that nitrite is capable of generating bioactive NO in the corpora
cavernosa. Soluble guanylate cyclase stimulators (YC-1, A-350619, CFM-1571, and the Bayer compounds BAY 41-2272, BAY 41-8543, and
BAY 63-2521) have been shown to act directly on the sGC enzyme and synergize with available NO which could be beneﬁcial in disease states
with low NO production and bioavailability. sGC activators (BAY 58-2667, BAY 60-2770 and HMR 1766/S3448) have also been shown to act
on oxidized and heme-deﬁcient sGC. Rho-kinase/RhoA activation has been shown to mediate detumescence and maintain ﬂaccidity. Rho
kinase inhibits the regulatory subunit of myosin phosphatase within smooth muscle cells and maintains contractile tone under low-cytosolic
calcium concentrations. Upregulated Rho-kinase activity has been reported in ED, so Rho-kinase inhibitors (Y-27632 and SAR 407899) have
potent erectile eﬀects and oﬀer another therapeutic target for the treatment of ED.
The outcome of these processes is hemolytic endothelial
dysfunction in which there is abnormal activity of important
vasoactive signaling molecules and mechanisms such as
NO, PDE-5, adenosine, and Rho-kinase. The destruction of
corporal endothelium and smooth muscle that occurs with
ischemic priapism often results in ED [44]. Priapism may
also result from the use of erectile function promoting agents
that have a long duration of action.Advances in Pharmacological Sciences 5
5.NeedforAlternativeTherapies
Pathologic conditions involving impaired NO synthesis can
lead to ED that is refractory to treatments with PDE-5
inhibitors. Clinical trials for the PDE-5 inhibitor sildenaﬁl
reported that up to 40% of patients with diabetes and 50%
of patients postprostatectomy did not respond to treatment
[47]. In these conditions a small amount of NO is released
and activation of sGC is minimal so that adequate levels of
cGMP to facilitate erection are not reached [48]. The aim of
this paper is to discuss 3 types of new pharmacotherapies
that have surfaced in the last decade and may provide
an alternative to current options for treatment of ED in
the future. These emerging treatments are summarized in
Figure 1 along with the pathway mediating erection.
6.sGCStimulators/Activators
Nitric oxide is the key mediator of the erectile process.
Under normal physiologic conditions activation of the
heterodimerichemeproteinsolubleguanylylcyclase(sGC)is
basedupontheinteractionofNOwithahemeiron,breaking
of an Fe–His bond and a change in the conformation of sGC
to its active form. It has been demonstrated that activity can
occur in an NO-independent manner with protoporphyrin
IX [49–51]. The need for therapies that bypass the NO
stimulatingstepbutcanstillactivatethesGC-cGMPpathway
has led to the development and use of sGC stimulators and
activators.
In 1994, a team led by Feng-Nien Ko reported on a
benzylindazole compound, YC-1 [3-(5-hydroxymethyl-2-
furyl)-1-benzylindazole], that prolonged tail bleeding time
of conscious mice, demonstrated direct guanylate cyclase
activation in rabbit platelets, and increased cGMP levels
independent of NO [52]. YC-1 has vasodilator activity and
the compound synergizes with NO to increase vasodilatory
responses to NO donors [53]. YC-1 was shown to have
erectile activity in the rat after intracavernosal (ic) injection
and also to enhance erectile responses to apomorphine and
cavernous nerve stimulation when administered systemically
[54]. The research with the ﬁrst sGC stimulator provided a
basis for the development of the next generation stimulators
with improved potency and sGC speciﬁcity including CFM-
1571, and the Bayer compounds BAY 41-2272, BAY 41-8543
and BAY 63-2521 [55–58].
Experiments with BAY 41-2272 and the heme-removal
detergent Tween-20 showed that the sGC stimulator has
no bioactivity on a heme-free sGC enzyme [56]. It was
also suggested through photo-aﬃnity labeling that the BAY
compound does not directly bind the heme moiety but
instead interacts with the α1-unit of sGC [56]. It was
determined that BAY 41-2272 increased sGC activity 20
fold over baseline in the absence of NO and the response
was potentiated further with the addition of the NO donor
DEA/NO [56].sGC stimulators can act independently of NO
aswellassynergize withNO, however, theyrequirea reduced
heme moiety for bioactivity [59]. The mechanism of action
for these stimulators has not been completely elucidated;
however, it has been proposed that NO-YC-1 synergy exists
because the stimulator maintains the active conformation of
sGCthroughstabilizationofthenitrosyl-hemecomplex[60–
62]. It was shown that oxidized derivatives of both BAY 41-
2272 and BAY 41-8543 remained bioactive in experiments
with rats and dogs, suggesting a role for the metabolites of
these sGC stimulators and their potential residual beneﬁt in
vivo [63].
The properties of another novel sGC stimulator, A-
350619, were investigated in a conscious Wistar rat model
and induced penile erection after intraperitoneal injection
[64]. BAY 41-2272 was administered to rabbits and initiated
a small erectile response similar to sildenaﬁl which was
hypothesized to be weak due to lack of sexual stimulation
[65, 66]. The erectile responses to BAY 41-2272 were signif-
icantly enhanced with concurrent administration of the NO
donorsodiumnitroprusside(SNP),demonstratingasynergy
between the compound and NO [67]. A comparative study
of sildenaﬁl, an NO releasing sildenaﬁl agent (NCX-911),
and BAY 41-2272 in streptozotocin-induced diabetic rats
demonstrated that NO relaxation responses were reduced
and the diminished relaxation responses were potentiated by
BAY 41-2272, but not by sildenaﬁl or NCX-911 [67]. These
results provided further evidence for the eﬀectiveness of sGC
stimulators in ED that presents concomitantly with disease
states involving impaired NO release.
In addition to heme-dependent stimulators, an NO and
heme-independent class of sGC activators (BAY 58-2667,
BAY 60-2770 and HMR 1766/S3448) has been introduced
that target an altered form of sGC associated with many dis-
ease states, although low levels of heme-free sGC have been
reported in normal physiologic states as well [68–70]. Initial
characterization of the actions of the heme-independent
sGC activator BAY 58-2667 demonstrated potent baseline
stimulation, but only additive eﬀects with NO donors on
puriﬁed sGC activity [68, 71, 72]. Interestingly, it was shown
thatasigniﬁcantincreaseinbioactivityoccurswithoxidation
of sGC by ODQ or removal of the heme complex from
the enzyme [68, 71]. BAY 58-2667 has been reported to
preferentially target the heme pocket of sGC and alter the
enzyme to resemble the NO-active form [73]. Although it
is accepted that oxidization weakens the binding of sGC
to the heme prosthetic group, it remains controversial if
the sGC activator removes the weakened prosthetic group
before inserting itself or if the bioactivity is dependent on an
enzyme that has already lost the heme complex [69, 74].
sGC activators have been shown to have beneﬁcial eﬀects
in animal models of CVD, liver ﬁbrosis, renal disease,
ischemia-reperfusion-induced injury, thrombosis, systemic
hypertension and pulmonary hypertension [73]. The use of
sGC activators for ED has not been determined and pilot
studies are needed to assess their utility in the treatment
of this disease. The oxidative stress present in many disease
states that present with ED suggests a potential role for
the use of these activators in treating ED. The use of both
sGC activators and stimulators is promising in conditions of
altered heme conformation as well as in conditions where
NO synthesis is impaired such as diabetes, hypertension, or
prostatectomy in which there was neural damage [54, 59, 66,
75–78].6 Advances in Pharmacological Sciences
7.Rho-KinaseInhibitors
When the penis is ﬂaccid, cavernous smooth muscle as well
as smooth muscle of arterioles is predominantly contracted
and allows minimal arterial inﬂow to the tissues [79].
Smooth muscle contraction and relaxation is related to the
level of free cytosolic calcium in the cell. Norepinephrine,
endothelin-1 and prostaglandin F2α activate receptors on
smooth muscle cells to increase intracellular levels of inositol
triphosphate (IP3) and diacylglycerol (DAG) via a phos-
pholipase C (PLC) mediated pathway. The accumulation of
these intracellular messengers facilitates the release of Ca2+
from store and the opening of calcium channels on the cell
membrane. The increase of intracellular Ca2+ concentration
results in calcium binding to calmodulin and activation of
myosin light chain kinase [80]. Phosphorylated myosin light
chains trigger cycling of myosin crossbridges along actin
ﬁlaments and generation of force as well as activation of
myosin ATPase which hydrolyzes ATP to provide necessary
energy for contraction.
When intracellular calcium levels return back to basal
level,asensitizationpathwaytakesplacewithRhoAandRho-
kinase. RhoA is a small, monomeric G protein that activates
Rho-kinase. Rho-kinase phosphorylates and inhibits the
regulatory subunit of myosin phosphatase within smooth
muscle cells. This action maintains phosphorylation of
myosin ﬁlaments and contractile tone within the smooth
muscle [81]. Vasodilation of arteries in the corpora is
largely responsible for mediating the erectile process, and
inhibition of the calcium sensitization pathway with Rho-
kinaseinhibitorsoﬀersatherapeuticoptionforthetreatment
of ED that does not involve the direct targeting of the
NO/sGC/cGMP pathway.
Ic injections of the Rho-kinase inhibitor Y-27632 in
rats pretreated with NOS inhibitors (L-NNA and L-NAME)
or sGC inhibitors (methylene blue and ODQ) resulted in
increased erectile activity in response to nerve stimulation
seemingly independent of NO [82]. It was also proposed
that NO may act to inhibit the RhoA/Rho-kinase pathway
in the normal erectile response [83, 84]. Increases in intra-
cavernosal pressure (ICP) were observed with ic injections
alone without nerve stimulation, which provided evidence
for a constant role for the RhoA/Rho-kinase pathway in
maintaining ﬂaccidity in the penis [82]. Rat cavernosum
transfected with an adeno-associated viral gene dominant
negative RhoA mutant (T19NRhoA) showed enhanced erec-
tile activity providing further support for the role of RhoA
in maintaining the ﬂaccid state of the penis [85]. Western
blot analysis in human corpus cavernosum tissue veriﬁed the
presence and activity of RhoA/Rho-kinase in human penile
cavernosal smooth muscle [86].
It has been shown that endothelial dysfunction and
impaired NOS activity in the corpora cavernosum largely
contributes to ED in diabetic men [87, 88]. A mechanism
for diabetes-induced erectile dysfunction was demonstrated
in which upregulated RhoA/Rho-kinase levels were found
in cavernosal tissue of streptozotocin-induced diabetic rats.
Erectile activity, cavernosal eNOS protein, constitutive NOS
activity, and cGMP levels were restored to levels found in
control animals after transfection with a dominant negative
RhoA mutant [89]. Chronic administration of the Rho-
kinase inhibitor fasudil was shown to prevent vasculogenic
ED while reducing levels of pelvic atherosclerosis in a rat
model receiving atherosclerosis-prone treatments [90]. A
more recent study suggested that diabetic-associated ED
due to upregulation of the penile RhoA/Rho-kinase pathway
enhances PTEN/Akt activity leading to corporal apoptosis
[91]. The study also suggested that chronic administration
of the Rho-kinase inhibitor fasudil is more eﬀective at
reversingthesedetrimentalbiochemicalchangesthaninsulin
administration in diabetic rats [91]. Further research is
needed to determine if the reduced atherosclerosis and
improved erectile activity could be observed in patients with
severe CVD and/or diabetes.
Human clinical trials have recently been performed
using SAR407899, a Rho-kinase inhibitor four times more
potent than fasudil, for the treatment of mild to moderate
ED (Rhoket trials—Aventis). Statins are used clinically as
powerful lipid lowering agents. These compounds also have
the ability to block the formation of isoprenoid inter-
mediates required for RhoA activity [92]. It was recently
shown that low-dose atorvastatin (Lipitor) normalizes the
diabetic response to sildenaﬁl in STZ-treated diabetic rats
suggesting an inhibitory role of statins upon the RhoA/Rho-
kinase pathway [93]. A clinical trial was recently concluded
demonstrating the safety of the concurrent use of the PDE-
5 inhibitor vardenaﬁl with statins, thus oﬀering a potential
beneﬁt to many men suﬀering from dyslipidemic conditions
such as Type II diabetes and ED [94].
8.IntracavernosalSodiumNitriteasa
Novel NO Donor
It has been hypothesized that the nitrite anion is an impor-
tantreservoirofcirculatingNO.Nitritewasusedclinicallyby
Brunton and co-workers for the treatment of angina pectoris
and for lowering blood pressure a century and a half ago
[95–97]. In animal models nitrite has been shown to mediate
pulmonary vasodilation and prevent ischemia-reperfusion
injury in the brain, liver, and heart [98–100]. The use of
intracavernosal NO donors such as SNP to treat ED has
been controversial because of hypotensive side eﬀects [101,
102]. We have recently shown in the rat that sodium nitrite
(NaNO2) administered ic increases ICP, decreases systemic
arterial pressure and is 1000-fold less potent than the NO
donor SNP [103]. Experiments with the NOS inhibitor L-
NAME and the xanthine oxidoreductase (XOR) inhibitor
allopurinol suggest a mechanism of nitrite bioactivation in
the corpora that is mediated through eNOS, whereas nitrite
bioactivation in the systemic vascular beds is largely due
to the activity of XOR [100, 103]. The ability of nitrite to
enhance erectile activity suggests further investigation in the
use of nitrite as a therapeutic agent for ED.
9. Conclusion
The worldwide prevalence of ED in society requires new
treatments for the growing number of patients withAdvances in Pharmacological Sciences 7
comorbid conditions that have become refractory to typical
PDE-5 therapy. In the past ten years, the emergence of sGC
stimulators/activators, Rho-kinase inhibitors and novel NO
donors oﬀers therapeutic potential for patients in which
NO release and/or synthesis is impaired. Further research
is needed to demonstrate the safety and eﬃcacy of these
therapies for the treatment of ED.
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